Diag Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Diag Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$1.42M	Buy	+38,319	New	+$1.38M	1.62%	23

Other funds holding BHVN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Diag Capital Management's BHVN Position: Q4 2018 in Review

Diag Capital Management opened a new position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2018: 38,319 shares worth $1.42M. The stake represents 1.62% of the portfolio and ranks #23 among its holdings.

131 funds tracked by Wall St. Rank hold BHVN as of Q4 2018.

Diag Capital Management held 38,319 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $1.42M as of Q4 2018.
Biohaven Pharmaceutical Holding Company Ltd. was a new Diag Capital Management position in Q4 2018.
Biohaven Pharmaceutical Holding Company Ltd. made up 1.62% of Diag Capital Management's portfolio in Q4 2018, its #23 holding.
131 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2018.

Based on Diag Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.